C
horiocarcinoma is a rapidly growing, highly invasive and widely metastasizing human chorionic gonadotropin (hCG)-producing epithelial tumor with differentiation towards a villous trophoblast phenotype. 1 It arises mainly from trophoblastic germ cells and is usually of endometrial origin but may be extragonadal. 2 The pure type of choriocarcinoma is uncommon. Mixed types that consist of choriocarcinoma and adenocarcinoma are more frequent. Gastric cancer is a major contributor to the global burden of cancer morbidity and mortality. 3 Primary gastric chorioadenocarcinoma (PGC) constitutes less than 1% of all gastric cancers 4 and serum beta-hCG serves postoperatively as a serum marker of tumor recurrence. Approximately 30% of patients already have metastatic disease at diagnosis. 5 Due to the coexistence of adenocarcinoma and choriocarcinoma, PGC is often misdiagnosed as an adenocarcinoma. 6 The presenting signs and symptoms of upper gastrointestinal hemorrhage (melena and weight loss) are similar to typical gastric adenocarcinoma. We treated a patient with PGC with a non-gestational choriocarcinoma chemotherapy regimen, which gave a complete serological response after four cycles.
C A S E R E P O RT
A 56-year-old man with no relevant medical or surgical history presented with epigastric pain, persistent indigestion, tarry stool, and weight loss.
An oesophago-gastro-duodenoscopy (OGD) was performed and showed two large ulcerated gastric mass lesions; one along the lesser curvature and one in the distal stomach with spontaneous oozing of blood. Multiple biopsies were taken. A subsequent computed tomography (CT) scan showed gastric wall thickening within the lesser curvature; a large exophytic mass and multiple coeliac and gastrohepatic ligament lymph nodes enlargement [ Figure 1 and 2].
Serum tumor markers tests were obtained; his carcinoembryonic antigen (CEA) level was 35.5 ng/ ml and alpha-fetoprotein (AFP) was 50.26 mU/mL.
The patient underwent a staging laparoscopy followed by an open total gastrectomy. Histological evaluation of the gastrectomy specimen demonstrated an ulcerated and invasive neoplasm composed of cells arranged in sheets and nests. The tumor showed areas of conventional adenocarcinoma [ Figure 3 ] with focal areas of cytotrophoblastic and syncytiotrophoblastic differentiation, consistent with a gastric choriocarcinoma [ Figure 4 ]. Vascular and perineural invasion were present and out of the 57 lymph nodes examined, 23 showed metastasis from the tumor, which had a similar histopathologic appearance. Positive cytokeratin staining was seen in the entire tumor. The neoplastic cells were positive for pan-cytokeratin (CK) and CK7 and showed focally immunoreactivity for beta-hCG [ Figure 5 ] and human epidermal growth factor receptor 2 (Her-2) [ Figure 6 ]. The cells were negative for CD20, human melanoma black (HMB)-45, hepatocyte paraffin 1 
A B S T R AC T
Primary gastric chorioadenocarcinoma (PGC) is a rare and rapidly invasive tumor. Choriocarcinoma is usually known to be of endometrial origin and gestational; however, it has been reported in other extragenital organs, such as the gall bladder, prostate, lung, liver, and the gastrointestinal tract. Human chorionic gonadotropin related neoplasms of the stomach are seldom discussed in the literature. We report a case of PGC in a 56-year-old man treated with a standard non-gestational choriocarcinoma chemotherapy regimen, EMA/CO (etoposide, methotrexate, actinomycin D, cyclophosphamide, vincristine), with a complete response and good tolerability.
(Hep Par1) and AFP. Based on the above features, a diagnosis of a choriocarcinoma-like variant of gastric adenocarcinoma was made.
The patient had an unremarkable postoperative course. Serial serum beta-hCG levels after surgery showed a significant decline to 7 mU/mL 26 days later. Then the patient was treated with a standard non-gestational choriocarcinoma chemotherapy regimen, in the form of four cycles of EMA/ CO (etoposide, methotrexate, actinomycin D, cyclophosphamide, vincristine). A CT scan after the treatment did not show any evidence of recurrent tumor. Serum beta-hCG levels dropped to 1 mU/ mL after chemotherapy and remained normal 12 months later.
D I S C U S S I O N
PGC was first described by Davidsohn in 1905 and, to date, more than 140 cases have been reported in the international medical literature. 7 Several studies revealed that the pathogenesis of PGC can be explained by the dedifferentiation of malignant adenocarcinoma tissue to the level of the embryonal ectoderm, retaining the ability to form trophoblasts. 8 This is known as the dedifferentiation theory, 9 and was proposed by Pick in 1926 and now it is widely accepted. 10 Nevertheless, pathogenesis is still a subject of controversy.
There are few reported cases of primary gastric choriocarcinomas, and it reveals that these types of neoplasms behave more like gestational or germ cell choriocarcinomas with early and extensive hematogenous dissemination rather than the usual lymphatic way of adenocarcinomas. Characteristically, lymph nodes were the most common sites for metastases (87%) followed by the liver (45%), peritoneum (23%), and lung (8%). 11 The clinical presentation of PGC does not differ much from gastric adenocarcinoma except it has rapid progression, metastatic disease at diagnosis, and the elevated beta-hCG can cause morning sickness-like symptoms in women and gynecomastia in men. 12 PGC has a poor prognosis, high mortality, and a short survival rate unlike primary gastric adenocarcinoma, which has an overall five-year survival rate of 50% for those patients who present earlier with the resectable disease. 13 The effective standard treatment regimen for PGC has not been yet established and is still controversial given limited data from the available literature.
C O N C LU S I O N
PGC is an exceedingly rare and interesting neoplasm that is commonly misdiagnosed as adenocarcinoma. Making the correct diagnosis demands a high index of suspicion coupled with the appropriate utilization of beta-hCG immunostains.
The response of this case to the standard nongestational choriocarcinoma chemotherapy regimen (EMA/CO) may help to add another piece to the jigsaw puzzle of the optimal treatment, but more studies and larger clinical trials are needed to define the appropriate and standard treatment.
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